ArticleAsian Pacific journal of cancer prevention : APJCP2025
Different Immunohistochemical Expression of CTLA-4 in Diffuse Large B-Cell Lymphoma and Its Associated Prognostic Factors.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Immunohistochemical expression of PD1, LAG3, and CTLA4 in diffuse large B cell lymphoma, clinicopathological correlation, and prognostic value.Journal of the Egyptian National Cancer Institute · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is classified into germinal center B-cell-like (GCB) and non-GCB subtypes. This study aimed to evaluate the immunohistochemical expression of CTLA-4 in these subtypes and its association with prognostic factors.
methodsThis retrospective study analyzed 50 cases of DLBCL. Clinical and histopathological data were collected, and CTLA-4 expression was assessed using immunohistochemistry. Statistical significance was determined using an unpaired t-test.
resultThe average CTLA-4 expression in DLBCL was 50.46 cells per high-power field. Higher CTLA-4 expression was observed in the non-GCB subtype, patients younger than 60 years, females, those with stage III-IV disease, involvement of more than one extranodal site, and a low International Prognostic Index (IPI) score (0-2). A significant association was found between CTLA-4 expression and age (p = 0.045, 95% CI: 44.67-75.86).
conclusionCTLA-4 expression was present in the tumor microenvironment of DLBCL. Higher expression was significantly associated with patients younger than 60 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.